Landscape → Oncology

Bladder Cancer Clinical Trial Landscape

Data updated: May 20, 2026

959 clinical trials tracked since 2008

Bladder cancer occurs when cells in the bladder grow uncontrollably, and it is most common in older adults. Clinical research is crucial for developing new and improved treatments for this disease. Since 2008, 954 bladder cancer trials have been registered, with 438 currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 1 and Phase 2, with 175 and 256 trials respectively, suggesting a strong focus on early-stage drug development. Phase 3 trials account for 83 active trials, while Phase 4 trials are less common, with only 9 active. Industry sponsorship is led by Merck, with 11 active trials, followed by AstraZeneca with 9, and Pfizer, Mabwell (Shanghai) Bioscience Co., Ltd., and Roche with 5 and 4 active trials respectively. The high number of Phase 1 and 2 trials compared to Phase 3 and 4 suggests an emphasis on exploring novel therapeutic approaches.

439 active

959 total (since 2008)

175

Phase 1 Active

414 total

258

Phase 2 Active

567 total

Phase 3 Active

135 total

Phase 4 Active

16 total

Top Industry Sponsors

Sorted by active Active Done Failed

Merck 11 6 1

AstraZeneca 9 2 0

Pfizer 5 2 10

Mabwell (Shanghai) Bioscience Co., Ltd. 5 0 0

Roche 4 8 3

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT03244384 ACTIVE NOT RECRUITING

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

National Cancer Institute (NCI) n=739

NCT05987241 RECRUITING

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI) n=992

NCT04628767 RECRUITING

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI) n=249

NCT07129993 RECRUITING

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo n=630

NCT04579224 ACTIVE NOT RECRUITING

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI) n=184

+ 130 more Phase 3 trials — see full database below

Bladder Cancer — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Merck

AstraZeneca

Pfizer

Mabwell (Shanghai) Bioscience Co., Ltd.

Roche

Astellas Pharma Global Development, Inc.

Ferring Pharmaceuticals

Bristol-Myers Squibb

ImmunityBio, Inc.

Johnson & Johnson

Active Trials by Phase

Phase 1

175

Phase 2

258

Phase 3

Phase 4

Enrollment Size Distribution

1-50

451

51-200

289

201-500

109

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Merck 11 6 1

AstraZeneca 9 2 0

Pfizer 5 2 10

Mabwell (Shanghai) Bioscience Co., Ltd. 5 0 0

Roche 4 8 3

Astellas Pharma Global Development, Inc. 4 3 2

Ferring Pharmaceuticals 4 1 1

Bristol-Myers Squibb 4 1 1

ImmunityBio, Inc. 4 0 1

Johnson & Johnson 4 0 0

UroGen Pharma Ltd. 3 4 1

CG Oncology, Inc. 3 2 2

RemeGen Co., Ltd. 3 3 0

BeiGene 3 1 0

Sichuan Baili Pharmaceutical Co., Ltd. 3 0 0

NCT03244384 ACTIVE NOT RECRUITING

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

National Cancer Institute (NCI) n=739

NCT05987241 RECRUITING

National Cancer Institute (NCI) n=992

NCT04628767 RECRUITING

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI) n=249

NCT07129993 RECRUITING

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo n=630

NCT04579224 ACTIVE NOT RECRUITING

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI) n=184

NCT06524544 RECRUITING

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI) n=320

NCT05092958 ACTIVE NOT RECRUITING

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

National Cancer Institute (NCI) n=654

NCT06510374 RECRUITING

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Ferring Pharmaceuticals n=454

NCT07106762 RECRUITING

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Bristol-Myers Squibb n=470

NCT03390504 ACTIVE NOT RECRUITING

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Janssen Research & Development, LLC n=629

NCT05243550 ACTIVE NOT RECRUITING

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. n=240

NCT06929286 RECRUITING

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Memorial Sloan Kettering Cancer Center n=125

NCT07566156 RECRUITING

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )

Astellas Pharma Global Development, Inc. n=390

NCT05714202 ACTIVE NOT RECRUITING

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Janssen Research & Development, LLC n=1,135

NCT06545955 RECRUITING

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Ferring Pharmaceuticals n=250

NCT07419295 RECRUITING

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Merck Sharp & Dohme LLC n=590

NCT05506943 ACTIVE NOT RECRUITING

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Compass Therapeutics n=168

NCT05538663 ACTIVE NOT RECRUITING

Intravesical BCG vs GEMDOCE in NMIBC

ECOG-ACRIN Cancer Research Group n=870

NCT07097142 RECRUITING

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NRG Oncology n=486

NCT03775265 ACTIVE NOT RECRUITING

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI) n=475

NCT03711032 ACTIVE NOT RECRUITING

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Merck Sharp & Dohme LLC n=1,397

NCT06774131 RECRUITING

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

UroGen Pharma Ltd. n=70

NCT03967977 ACTIVE NOT RECRUITING

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

BeiGene n=420

NCT06225596 ACTIVE NOT RECRUITING

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

BicycleTx Limited n=956

NCT02516241 ACTIVE NOT RECRUITING

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

AstraZeneca n=1,126

NCT06857175 RECRUITING

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

Sichuan Baili Pharmaceutical Co., Ltd. n=508

NCT05911295 ACTIVE NOT RECRUITING

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Seagen, a wholly owned subsidiary of Pfizer n=412

NCT03661320 ACTIVE NOT RECRUITING

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Bristol-Myers Squibb n=855

NCT03528694 ACTIVE NOT RECRUITING

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

AstraZeneca n=1,018

NCT05059522 ACTIVE NOT RECRUITING

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer n=68

NCT04960709 ACTIVE NOT RECRUITING

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

AstraZeneca n=712

NCT07526792 NOT YET RECRUITING

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

CSPC Megalith Biopharmaceutical Co.,Ltd. n=406

NCT07000084 RECRUITING

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Alliance for Clinical Trials in Oncology n=330

NCT04660344 ACTIVE NOT RECRUITING

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

Hoffmann-La Roche n=761

NCT03091660 ACTIVE NOT RECRUITING

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

SWOG Cancer Research Network n=1,000

NCT05037279 RECRUITING

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

Verity Pharmaceuticals Inc. n=540

NCT04637594 ACTIVE NOT RECRUITING

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Alliance for Clinical Trials in Oncology n=3

NCT07480356 NOT YET RECRUITING

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Protara Therapeutics n=284

NCT04452591 ACTIVE NOT RECRUITING

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

CG Oncology, Inc. n=190

NCT03732677 ACTIVE NOT RECRUITING

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

AstraZeneca n=1,063

NCT05943106 ACTIVE NOT RECRUITING

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

AstraZeneca n=100

NCT07464145 NOT YET RECRUITING

A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Relmada Therapeutics, Inc. n=393

NCT03036098 ACTIVE NOT RECRUITING

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Bristol-Myers Squibb n=1,314

NCT07393542 RECRUITING

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=462

NCT03682068 ACTIVE NOT RECRUITING

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

AstraZeneca n=1,246

NCT06703476 RECRUITING

A Study of Surgical Techniques During Cystectomy

Memorial Sloan Kettering Cancer Center n=530

NCT04165317 ACTIVE NOT RECRUITING

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Pfizer n=1,068

NCT07346053 NOT YET RECRUITING

The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer

Guliz Ozgun n=224

NCT06331299 ACTIVE NOT RECRUITING

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

UroGen Pharma Ltd. n=99

NCT06111235 ACTIVE NOT RECRUITING

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

CG Oncology, Inc. n=367

NCT05726786 RECRUITING

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)

Centre Hospitalier Universitaire Vaudois n=232

NCT06851663 RECRUITING

Trop2-targeted immunoPET Imaging of Solid Tumors

RenJi Hospital n=400

NCT07268339 NOT YET RECRUITING

A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.

The Christie NHS Foundation Trust n=328

NCT06525571 RECRUITING

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Johns Hopkins University n=200

NCT03022825 ACTIVE NOT RECRUITING

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc. n=190

NCT07198451 NOT YET RECRUITING

Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial

Shanghai University of Traditional Chinese Medicine n=320

NCT06124976 RECRUITING

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

University of British Columbia n=70

NCT03924856 ACTIVE NOT RECRUITING

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Merck Sharp & Dohme LLC n=907

NCT05704244 ACTIVE NOT RECRUITING

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Ferring Pharmaceuticals n=25

NCT03924895 ACTIVE NOT RECRUITING

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Merck Sharp & Dohme LLC n=595

NCT07067749 RECRUITING

Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

University of Rome Tor Vergata n=92

NCT02106572 ACTIVE NOT RECRUITING

Therapeutic Instillation of Mistletoe

Abnoba Gmbh n=548

NCT04574960 RECRUITING

Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)

University Health Network, Toronto n=14

NCT06738251 RECRUITING

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Shanghai Hengrui Pharmaceutical Co., Ltd. n=402

NCT04865939 RECRUITING

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

University of Texas Southwestern Medical Center n=132

NCT06879145 RECRUITING

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=840

NCT04223856 ACTIVE NOT RECRUITING

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Global Development, Inc. n=886

NCT05078047 RECRUITING

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

UNICANCER n=646

NCT06196736 RECRUITING

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd. n=432

NCT06214572 RECRUITING

Radiation Therapy in Unresectable Gall Bladder Cancer

Tata Memorial Centre n=249

NCT06493552 RECRUITING

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Vasgene Therapeutics, Inc n=700

NCT06364904 NOT YET RECRUITING

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=210

NCT06696794 RECRUITING

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Shaogang Wang n=180

NCT02951325 ACTIVE NOT RECRUITING

Bladder Cancer Adjuvant Radiotherapy Trial

Tata Memorial Centre n=153

NCT03799835 ACTIVE NOT RECRUITING

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

UNICANCER n=517

NCT06671418 ENROLLING BY INVITATION

Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction

Erasmus Medical Center n=148

NCT06592326 RECRUITING

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd. n=460

NCT05822934 ACTIVE NOT RECRUITING

Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer

Assiut University n=20

NCT06327932 NOT YET RECRUITING

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

Affiliated Cancer Hospital & Institute of Guangzhou Medical University n=320

NCT06241755 RECRUITING

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Chengdu CoenBiotech Co., Ltd n=412

NCT05302284 RECRUITING

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

RemeGen Co., Ltd. n=452

NCT03216525 RECRUITING

Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Brigham and Women's Hospital n=136

NCT05810623 NOT YET RECRUITING

Single-Dose Intravesical Chemotherapy After Diagnostic URS

David D'Andrea n=394

NCT04947059 RECRUITING

Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)

University of Thessaly n=180

NCT07313891 WITHDRAWN

A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Relmada Therapeutics, Inc.

NCT07342517 WITHDRAWN

A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

Relmada Therapeutics, Inc.

NCT07413120 COMPLETED

Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery

Incheon St.Mary's Hospital n=40

NCT04700124 COMPLETED

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

Merck Sharp & Dohme LLC n=808

NCT03898180 COMPLETED

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Merck Sharp & Dohme LLC n=505

NCT03474107 COMPLETED

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Global Development, Inc. n=608

NCT07279792 COMPLETED

Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection

Ain Shams University n=150

NCT04157985 COMPLETED

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Dan Zandberg n=161

NCT01812369 COMPLETED

Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer

University Hospital, Rouen n=500

NCT03374488 COMPLETED

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Incyte Corporation n=84

NCT03361865 COMPLETED

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Incyte Corporation n=93

NCT04527991 COMPLETED

Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Gilead Sciences n=712

NCT02807636 COMPLETED

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Hoffmann-La Roche n=1,213

NCT04806178 COMPLETED

Immunological Response of Bladder Cancer Patients Under BCG

University of Campinas, Brazil n=30

NCT01627197 COMPLETED

Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer

Sun Yat-sen University n=186

NCT05600322 COMPLETED

Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

Photocure n=158

NCT05136898 COMPLETED

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

UroGen Pharma Ltd. n=8

NCT02773849 COMPLETED

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Ferring Pharmaceuticals n=157

NCT04209114 COMPLETED

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bristol-Myers Squibb n=114

NCT04688931 TERMINATED

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. n=282

NCT06301308 WITHDRAWN

A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial

Second Xiangya Hospital of Central South University

NCT02603432 COMPLETED

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

Pfizer n=700

NCT02145871 COMPLETED

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

Memorial Sloan Kettering Cancer Center n=282

NCT04197986 TERMINATED

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

QED Therapeutics, a BridgeBio company n=39

NCT00942331 COMPLETED

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

National Cancer Institute (NCI) n=506

NCT02853305 COMPLETED

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

Merck Sharp & Dohme LLC n=1,010

NCT02426125 COMPLETED

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Eli Lilly and Company n=530

NCT02449239 COMPLETED

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

Sesen Bio, Inc. n=133

NCT03718754 COMPLETED

En-bloc vs Conventional Resection of Primary Bladder Tumor

David D'Andrea n=384

NCT01869413 COMPLETED

Tranexamic Acid During Cystectomy Trial (TACT)

Ottawa Hospital Research Institute n=354

NCT02563561 TERMINATED

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

Spectrum Pharmaceuticals, Inc n=62

NCT03224182 TERMINATED

A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)

Spectrum Pharmaceuticals, Inc n=118

NCT02256436 COMPLETED

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Merck Sharp & Dohme LLC n=542

NCT01438112 TERMINATED

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

CG Oncology, Inc. n=22

NCT02818725 COMPLETED

I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations

UNICANCER n=133

NCT03335059 TERMINATED

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.

Medical Enterprises Ltd. n=5

NCT01076387 COMPLETED

Randomized Trial Comparing Robotic and Open Radical Cystectomy

Memorial Sloan Kettering Cancer Center n=124

NCT02982395 TERMINATED

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Samyang Biopharmaceuticals Corporation n=36

NCT02660190 COMPLETED

Photodynamic Diagnosis (PDD) in Flexible Cystoscopy

Jørgen Bjerggaard Jensen n=696

NCT02240017 COMPLETED

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

Institut Claudius Regaud n=46

NCT02302807 COMPLETED

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Hoffmann-La Roche n=931

NCT03298958 WITHDRAWN

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

The University of Texas Health Science Center at San Antonio

NCT02560584 COMPLETED

A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting

Photocure n=304

NCT02471495 WITHDRAWN

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

Medical Enterprises Europe B.V.

NCT01469221 TERMINATED

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals, Inc n=47

NCT01310803 TERMINATED

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals n=1

NCT01475266 TERMINATED

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Nippon Kayaku Co., Ltd. n=51

NCT01410565 TERMINATED

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Spectrum Pharmaceuticals, Inc n=66

NCT00729287 COMPLETED

Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer

KU Leuven n=276

NCT00974818 TERMINATED

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Memorial Sloan Kettering Cancer Center n=50

NCT01284205 WITHDRAWN

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Bioniche Life Sciences Inc.

NCT06770582 RECRUITING

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

National Cancer Institute (NCI)

NCT03047213 ACTIVE NOT RECRUITING

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

National Cancer Institute (NCI)

NCT04164082 ACTIVE NOT RECRUITING

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

NCT03866382 RECRUITING

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

NCT07038343 RECRUITING

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Avenzo Therapeutics, Inc.

NCT03237780 ACTIVE NOT RECRUITING

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

NCT04216290 ACTIVE NOT RECRUITING

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

NCT05239624 RECRUITING

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT03854474 ACTIVE NOT RECRUITING

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

National Cancer Institute (NCI)

NCT07584733 NOT YET RECRUITING

Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma

RenJi Hospital

NCT07265947 RECRUITING

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences, Inc

NCT07061964 RECRUITING

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

National Cancer Institute (NCI)

NCT05868265 RECRUITING

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Memorial Sloan Kettering Cancer Center

NCT07579195 NOT YET RECRUITING

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

University of Washington

NCT06534983 RECRUITING

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

Hoffmann-La Roche

NCT04152499 ACTIVE NOT RECRUITING

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Klus Pharma Inc.

NCT05661955 ACTIVE NOT RECRUITING

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

BeiGene

NCT03601455 ACTIVE NOT RECRUITING

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Jonsson Comprehensive Cancer Center

NCT07576725 NOT YET RECRUITING

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

NCT02365597 ACTIVE NOT RECRUITING

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

NCT06668493 RECRUITING

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

Ferring Pharmaceuticals

NCT06733363 RECRUITING

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Roswell Park Cancer Institute

NCT07087860 RECRUITING

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Mayo Clinic

NCT06822010 RECRUITING

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Rutgers, The State University of New Jersey

NCT06503146 RECRUITING

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Cancer Institute (NCI)

NCT05796375 RECRUITING

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

White River Junction Veterans Affairs Medical Center

NCT06637423 RECRUITING

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Merck Sharp & Dohme LLC

NCT07414992 NOT YET RECRUITING

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT04752722 RECRUITING

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

NCT06682728 RECRUITING

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

University of California, Irvine

NCT07241793 RECRUITING

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Sun Yat-sen University

NCT05645692 ACTIVE NOT RECRUITING

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Hoffmann-La Roche

NCT05562830 RECRUITING

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Merck Sharp & Dohme LLC

NCT06814496 RECRUITING

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

University of Arizona

NCT04114136 RECRUITING

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Dan Zandberg

NCT07232602 RECRUITING

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

Merck Sharp & Dohme LLC

NCT05327530 ACTIVE NOT RECRUITING

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

EMD Serono Research & Development Institute, Inc.

NCT03682289 ACTIVE NOT RECRUITING

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Rahul Aggarwal

NCT07222488 RECRUITING

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Merck Sharp & Dohme LLC

NCT07283835 RECRUITING

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Lepu Biopharma Co., Ltd.

NCT04917809 ACTIVE NOT RECRUITING

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT04879329 RECRUITING

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Seagen, a wholly owned subsidiary of Pfizer

NCT07421700 RECRUITING

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Pfizer

NCT07322263 RECRUITING

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Michael A. O'Donnell

NCT07193511 RECRUITING

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Avenzo Therapeutics, Inc.

NCT07475806 RECRUITING

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Astellas Pharma Global Development, Inc.

NCT03317158 RECRUITING

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Noah Hahn, M.D.

NCT04953104 ACTIVE NOT RECRUITING

ARID1A and/or KDM6A Mutation and CXCL13 Expression

M.D. Anderson Cancer Center

NCT04895709 RECRUITING

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

NCT06388720 RECRUITING

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

National Cancer Center, Korea

NCT03609216 ACTIVE NOT RECRUITING

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Alliance for Clinical Trials in Oncology

NCT06695845 RECRUITING

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

NCT05406713 ACTIVE NOT RECRUITING

Pembrolizumab in Muscle-invasive Bladder Cancer

Matthew Galsky

NCT06503614 RECRUITING

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

John Sfakianos

NCT06567743 RECRUITING

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

CG Oncology, Inc.

NCT03093922 ACTIVE NOT RECRUITING

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT04138628 ACTIVE NOT RECRUITING

Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

Jørgen Bjerggaard Jensen

NCT02845323 ACTIVE NOT RECRUITING

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT07506057 RECRUITING

Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy

Xiujuan Qu

NCT06948552 RECRUITING

Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA

Henry Ford Health System

NCT02138734 ACTIVE NOT RECRUITING

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

NCT03473743 ACTIVE NOT RECRUITING

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Janssen Research & Development, LLC

NCT07475403 RECRUITING

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Tianjin Medical University Second Hospital

NCT06704191 RECRUITING

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Mayo Clinic

NCT07420517 RECRUITING

Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer

Paul Toren

NCT07498907 NOT YET RECRUITING

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Peking University First Hospital

NCT07492225 ACTIVE NOT RECRUITING

Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial

Changhai Hospital

NCT05489211 RECRUITING

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

NCT05923190 ACTIVE NOT RECRUITING

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Fox Chase Cancer Center

NCT07169734 RECRUITING

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Alentis Therapeutics AG

NCT04977453 RECRUITING

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

GI Innovation, Inc.

NCT07474064 NOT YET RECRUITING

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

chenxu

NCT03547973 RECRUITING

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Gilead Sciences

NCT07332351 NOT YET RECRUITING

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

University of Washington

NCT07468851 NOT YET RECRUITING

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Jiangsu Hansoh Pharmaceutical Co., Ltd.

NCT05269381 RECRUITING

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Mayo Clinic

NCT04585750 RECRUITING

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals, Inc

NCT07050771 RECRUITING

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

The Methodist Hospital Research Institute

NCT06488222 RECRUITING

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

University of Florida

NCT07460245 NOT YET RECRUITING

Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Gruppo Oncologico Italiano di Ricerca Clinica

NCT04940299 ACTIVE NOT RECRUITING

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

NCT06528990 RECRUITING

Telehealth Intervention for Ostomy Self-Management

City of Hope Medical Center

NCT02675829 ACTIVE NOT RECRUITING

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Memorial Sloan Kettering Cancer Center

NCT05335941 ACTIVE NOT RECRUITING

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

M.D. Anderson Cancer Center

NCT06047379 RECRUITING

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

NCT06434350 RECRUITING

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

M.D. Anderson Cancer Center

NCT05644041 RECRUITING

Intravesical Gem/Doce in Patients With NMIBC

University of Arizona

NCT06630416 RECRUITING

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Northwestern University

NCT06809140 RECRUITING

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Matthew Galsky

NCT04644068 ACTIVE NOT RECRUITING

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

AstraZeneca

NCT07221942 RECRUITING

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

Fox Chase Cancer Center

NCT05710848 RECRUITING

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

SURGE Therapeutics

NCT04848519 ACTIVE NOT RECRUITING

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Emory University

NCT07410676 RECRUITING

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Essen Biotech

NCT07030257 RECRUITING

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Tasca Therapeutics

NCT06483334 ACTIVE NOT RECRUITING

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Merck Sharp & Dohme LLC

NCT06470282 RECRUITING

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

University of California, San Francisco

NCT05137262 ACTIVE NOT RECRUITING

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

M.D. Anderson Cancer Center

NCT07412171 NOT YET RECRUITING

NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC

Peking University Third Hospital

NCT03520491 ACTIVE NOT RECRUITING

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Memorial Sloan Kettering Cancer Center

NCT06972615 NOT YET RECRUITING

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

BLATAM

NCT05775471 RECRUITING

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Jonsson Comprehensive Cancer Center

NCT07183319 RECRUITING

Circulating Tumor DNA Response In Urothelial Cancer

University of Oklahoma

NCT03768570 ACTIVE NOT RECRUITING

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Canadian Cancer Trials Group

NCT07374549 NOT YET RECRUITING

SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

CSPC Megalith Biopharmaceutical Co.,Ltd.

NCT06172478 RECRUITING

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

NCT05951179 RECRUITING

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Protara Therapeutics

NCT04630730 ACTIVE NOT RECRUITING

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Swiss Cancer Institute

NCT07341737 NOT YET RECRUITING

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

NCT03228667 ACTIVE NOT RECRUITING

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

NCT05651022 ACTIVE NOT RECRUITING

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Indaptus Therapeutics, Inc

NCT06305767 ACTIVE NOT RECRUITING

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Merck Sharp & Dohme LLC

NCT05544552 ACTIVE NOT RECRUITING

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Tyra Biosciences, Inc

NCT03744793 ACTIVE NOT RECRUITING

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

M.D. Anderson Cancer Center

NCT05656235 RECRUITING

Renal Retention in High Grade Upper Tract Urothelial Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02989584 ACTIVE NOT RECRUITING

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT03171025 ACTIVE NOT RECRUITING

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

University of Utah

NCT07314723 RECRUITING

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

NCT07307456 RECRUITING

Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration

Changhai Hospital

NCT07185945 NOT YET RECRUITING

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

Guru Sonpavde

NCT07285044 RECRUITING

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Mayo Clinic

NCT07296705 RECRUITING

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Fujian Medical University Union Hospital

NCT06511648 RECRUITING

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Spanish Oncology Genito-Urinary Group

NCT07279597 NOT YET RECRUITING

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Tongji Hospital

NCT04198766 ACTIVE NOT RECRUITING

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

NCT05327647 RECRUITING

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

CHU de Quebec-Universite Laval

NCT04863885 ACTIVE NOT RECRUITING

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

H. Lee Moffitt Cancer Center and Research Institute

NCT06263153 RECRUITING

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Yuanquan Yang

NCT00756639 ACTIVE NOT RECRUITING

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

M.D. Anderson Cancer Center

NCT06210490 RECRUITING

A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery

Peking University First Hospital

NCT06059547 ACTIVE NOT RECRUITING

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

CatalYm GmbH

NCT06943521 RECRUITING

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America, Inc.

NCT05912816 RECRUITING

Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

RenJi Hospital

NCT06091124 RECRUITING

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

RenJi Hospital

NCT07048457 RECRUITING

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

Yale University

NCT06265285 RECRUITING

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Mayo Clinic

NCT07261592 NOT YET RECRUITING

Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT07257718 NOT YET RECRUITING

The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial

Chiti Arturo

NCT07259226 RECRUITING

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

UNICANCER

NCT03945162 RECRUITING

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Theralase® Technologies Inc.

NCT04428554 RECRUITING

Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy

Institut Claudius Regaud

NCT03697850 ACTIVE NOT RECRUITING

Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

UNICANCER

NCT04386746 ACTIVE NOT RECRUITING

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04180371 ACTIVE NOT RECRUITING

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

BicycleTx Limited

NCT02420847 ACTIVE NOT RECRUITING

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

NCT03504163 ACTIVE NOT RECRUITING

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Memorial Sloan Kettering Cancer Center

NCT07225374 RECRUITING

Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC

Samsung Medical Center

NCT04724018 RECRUITING

Sacituzumab Govitecan Plus EV in Metastatic UC

Dana-Farber Cancer Institute

NCT05241340 ACTIVE NOT RECRUITING

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

The Methodist Hospital Research Institute

NCT05706129 RECRUITING

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

ITM Oncologics GmbH

NCT06829823 NOT YET RECRUITING

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

ImmunityBio, Inc.

NCT03978624 ACTIVE NOT RECRUITING

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

UNC Lineberger Comprehensive Cancer Center

NCT02621151 ACTIVE NOT RECRUITING

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

NYU Langone Health

NCT03693014 ACTIVE NOT RECRUITING

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Memorial Sloan Kettering Cancer Center

NCT03915678 RECRUITING

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Institut Bergonié

NCT05296564 RECRUITING

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

NCT07201675 NOT YET RECRUITING

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

Qilu Hospital of Shandong University

NCT05965856 RECRUITING

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

NCT07189793 NOT YET RECRUITING

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

First Affiliated Hospital of Wenzhou Medical University

NCT04678362 RECRUITING

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

Centre Francois Baclesse

NCT07184021 NOT YET RECRUITING

Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer

Assiut University

NCT06394570 RECRUITING

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

University of Texas Southwestern Medical Center

NCT06184516 RECRUITING

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

University of Florida

NCT05845814 ACTIVE NOT RECRUITING

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

Merck Sharp & Dohme LLC

NCT03185468 RECRUITING

Intervention of Bladder Cancer by CAR-T

Shenzhen Geno-Immune Medical Institute

NCT05318573 ACTIVE NOT RECRUITING

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Fujifilm Pharmaceuticals U.S.A., Inc.

NCT06571708 RECRUITING

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Columbia University

NCT05879653 RECRUITING

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

Kyoto University Hospital

NCT06683846 RECRUITING

Ivonescimab in the Treatment of Multiple Advanced Tumors

Fudan University

NCT07126119 RECRUITING

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Tianjin Medical University Second Hospital

NCT05864144 ACTIVE NOT RECRUITING

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

NCT06983210 RECRUITING

Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma

Nagoya University

NCT07122414 RECRUITING

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

Suzhou Forlong Biotechnology Co., Ltd

NCT05057013 ACTIVE NOT RECRUITING

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Cancer Research UK

NCT06364956 RECRUITING

Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT06632951 ACTIVE NOT RECRUITING

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

AbbVie

NCT06356155 RECRUITING

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

University of Michigan Rogel Cancer Center

NCT05756569 RECRUITING

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

NCT06971614 RECRUITING

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

ImmVira Pharma Co. Ltd

NCT07043972 RECRUITING

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

Fox Chase Cancer Center

NCT07064863 NOT YET RECRUITING

A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.

Queen's University

NCT05086692 RECRUITING

A Beta-only IL-2 ImmunoTherapY Study

Medicenna Therapeutics, Inc.

NCT05312671 RECRUITING

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT07034053 RECRUITING

Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Ekaterina Laukhtina

NCT07025174 RECRUITING

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

First Affiliated Hospital of Zhejiang University

NCT06663137 RECRUITING

Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

Relmada Therapeutics, Inc.

NCT04179162 ACTIVE NOT RECRUITING

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Memorial Sloan Kettering Cancer Center

NCT05712356 ACTIVE NOT RECRUITING

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Lisata Therapeutics, Inc.

NCT02717156 ACTIVE NOT RECRUITING

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

University of Southern California

NCT04140526 ACTIVE NOT RECRUITING

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

OncoC4, Inc.

NCT04375813 RECRUITING

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Robert Svatek

NCT06405425 RECRUITING

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Sichuan Baili Pharmaceutical Co., Ltd.

NCT06957561 NOT YET RECRUITING

Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Sun Yat-sen University

NCT06257017 RECRUITING

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Yung NA

NCT05535218 ACTIVE NOT RECRUITING

Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer

Claudia Guerrieri

NCT06904573 RECRUITING

Probiotics in Advanced Urothelial Carcinoma

Sun Yat-sen University

NCT05101096 ACTIVE NOT RECRUITING

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

Gilead Sciences

NCT04046094 ACTIVE NOT RECRUITING

Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

University of Kansas Medical Center

NCT04802876 ACTIVE NOT RECRUITING

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

SOLTI Breast Cancer Research Group

NCT06823427 RECRUITING

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Mabwell (Shanghai) Bioscience Co., Ltd.

NCT05024734 RECRUITING

Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids

Roland Seiler-Blarer

NCT06852287 RECRUITING

Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT02202772 ACTIVE NOT RECRUITING

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Guarionex J. Decastro

NCT06493370 RECRUITING

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

University of Kansas Medical Center

NCT06686381 NOT YET RECRUITING

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

American University of Beirut Medical Center

NCT05917158 RECRUITING

A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma

Jinling Hospital, China

NCT06732531 RECRUITING

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

Zhuhai Beihai Biotech Co., Ltd

NCT02710734 ACTIVE NOT RECRUITING

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Fox Chase Cancer Center

NCT04562311 ACTIVE NOT RECRUITING

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Sun Yat-sen University

NCT06341400 RECRUITING

RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Zhujiang Hospital

NCT04289779 ACTIVE NOT RECRUITING

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

Deepak Kilari

NCT04861584 RECRUITING

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Zhujiang Hospital

NCT04106115 RECRUITING

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

University College, London

NCT06632262 RECRUITING

A Phase 2 Clinical Study of ABSK061 and ABSK043

Abbisko Therapeutics Co, Ltd

NCT06639347 RECRUITING

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Shanghai Hengrui Pharmaceutical Co., Ltd.

NCT05620134 ACTIVE NOT RECRUITING

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics Inc

NCT06623162 NOT YET RECRUITING

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Fundación de investigación HM

NCT06079112 RECRUITING

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

NCT05229614 RECRUITING

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

CNAO National Center of Oncological Hadrontherapy

NCT06551896 NOT YET RECRUITING

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT05232136 RECRUITING

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

Binhui Biopharmaceutical Co., Ltd.

NCT06528483 NOT YET RECRUITING

Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

NCT06310369 NOT YET RECRUITING

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

European Organisation for Research and Treatment of Cancer - EORTC

NCT05531123 RECRUITING

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Fudan University

NCT06187506 RECRUITING

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Fudan University

NCT06378242 RECRUITING

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

RemeGen Co., Ltd.

NCT06354231 RECRUITING

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

Fudan University

NCT05200988 ACTIVE NOT RECRUITING

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

The Netherlands Cancer Institute

NCT06022757 RECRUITING

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Evopoint Biosciences Inc.

NCT06255964 NOT YET RECRUITING

A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer

SUNHO（China）BioPharmaceutical CO., Ltd.

NCT06227065 NOT YET RECRUITING

Precise Neoadjuvant Chemoresection of Low Grade NMIBC

University of Bern

NCT03379909 RECRUITING

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT05600127 RECRUITING

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

Erasmus Medical Center

NCT05957757 RECRUITING

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

RenJi Hospital

NCT05996952 NOT YET RECRUITING

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

West China Hospital

NCT05912205 NOT YET RECRUITING

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT04617756 RECRUITING

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract

Centre Hospitalier Universitaire de Nīmes

NCT05733000 RECRUITING

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

NCT04186013 ACTIVE NOT RECRUITING

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Spanish Oncology Genito-Urinary Group

NCT03844256 RECRUITING

A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT03836352 ACTIVE NOT RECRUITING

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

ImmunoVaccine Technologies, Inc. (IMV Inc.)

NCT05072600 RECRUITING

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Peking University First Hospital

NCT03179943 ACTIVE NOT RECRUITING

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Fox Chase Cancer Center

NCT02447549 ACTIVE NOT RECRUITING

Study of Tumour Focused Radiotherapy for Bladder Cancer

Institute of Cancer Research, United Kingdom

NCT07591805 NOT YET RECRUITING

HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC

RenJi Hospital

NCT03375307 SUSPENDED

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

NCT04902872 COMPLETED

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Cybrexa Therapeutics

NCT07568444 COMPLETED

Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)

University of Southern California

NCT04902040 TERMINATED

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

M.D. Anderson Cancer Center

NCT05581589 TERMINATED

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

University of Washington

NCT05219435 COMPLETED

Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Spanish Oncology Genito-Urinary Group

NCT05077709 COMPLETED

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

IO Biotech

NCT02143804 WITHDRAWN

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

CG Oncology, Inc.

NCT05226117 COMPLETED

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

IRCCS San Raffaele

NCT03288545 TERMINATED

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Astellas Pharma Global Development, Inc.

NCT02690558 COMPLETED

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

UNC Lineberger Comprehensive Cancer Center

NCT03652298 TERMINATED

Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners

Centre Oscar Lambret

NCT01616875 COMPLETED

Bristol Bladder Trial

University Hospitals Bristol and Weston NHS Foundation Trust

NCT06171789 TERMINATED

PRO1107 in Patients With Advanced Solid Tumors

Genmab

NCT04426669 COMPLETED

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Intima Bioscience, Inc.

NCT05000294 SUSPENDED

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

NCT04856189 TERMINATED

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Mamta Parikh

NCT03869190 COMPLETED

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Hoffmann-La Roche

NCT04701918 COMPLETED

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Massachusetts General Hospital

NCT05512377 TERMINATED

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Boehringer Ingelheim

NCT04260802 TERMINATED

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

NCT04553939 COMPLETED

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Henan Cancer Hospital

NCT04601857 TERMINATED

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Taiho Oncology, Inc.

NCT04779151 TERMINATED

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Gustave Roussy, Cancer Campus, Grand Paris

NCT02625961 COMPLETED

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Merck Sharp & Dohme LLC

NCT02316548 TERMINATED

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

NRG Oncology

NCT04003610 TERMINATED

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Incyte Corporation

NCT03747419 TERMINATED

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Dana-Farber Cancer Institute

NCT04586244 TERMINATED

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Incyte Corporation

NCT05564416 WITHDRAWN

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

National Cancer Institute (NCI)

NCT01382706 TERMINATED

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

University of Southern California

NCT04995419 COMPLETED

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

Astellas Pharma China, Inc.

NCT03914794 COMPLETED

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04985604 TERMINATED

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

NCT04383743 COMPLETED

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

University of Washington

NCT04887831 TERMINATED

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

G1 Therapeutics, Inc.

NCT05259696 COMPLETED

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Palleon Pharmaceuticals, Inc.

NCT04936230 TERMINATED

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

National Cancer Institute (NCI)

NCT02872714 COMPLETED

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Incyte Corporation

NCT01261728 COMPLETED

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Memorial Sloan Kettering Cancer Center

NCT04570410 COMPLETED

Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma

The First Affiliated Hospital with Nanjing Medical University

NCT02769962 COMPLETED

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Cancer Institute (NCI)

NCT02553642 COMPLETED

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Memorial Sloan Kettering Cancer Center

NCT05714553 TERMINATED

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

NCT03502785 COMPLETED

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Inovio Pharmaceuticals

NCT05563272 TERMINATED

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Telix Pharmaceuticals (Innovations) Pty Ltd

NCT02015104 COMPLETED

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

National Cancer Institute (NCI)

NCT03081858 COMPLETED

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Lipac Oncology LLC

NCT05687721 WITHDRAWN

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

NCT05253053 COMPLETED

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

TransThera Sciences (Nanjing), Inc.

NCT04068896 COMPLETED

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NGM Biopharmaceuticals, Inc

NCT02844816 COMPLETED

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

NCT04383938 COMPLETED

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Aprea Therapeutics

NCT03406650 COMPLETED

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.

Swiss Cancer Institute

NCT01437488 COMPLETED

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT02122172 TERMINATED

Afatinib in Advanced Refractory Urothelial Cancer

University of Chicago

NCT04602078 COMPLETED

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Spanish Oncology Genito-Urinary Group

NCT04294277 TERMINATED

Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery

European Association of Urology Research Foundation

NCT04383210 TERMINATED

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

NCT02052778 COMPLETED

A Study of TAS-120 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

NCT02365766 COMPLETED

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Jason R. Brown

NCT04629339 TERMINATED

Study of INCB086550 in Select Solid Tumors

Incyte Corporation

NCT02662309 COMPLETED

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

Queen Mary University of London

NCT03871036 COMPLETED

Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

The Netherlands Cancer Institute

NCT02567409 COMPLETED

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

NCT05126433 TERMINATED

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

Jazz Pharmaceuticals

NCT03674424 COMPLETED

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

Jules Bordet Institute

NCT04322643 TERMINATED

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Case Comprehensive Cancer Center

NCT03197571 WITHDRAWN

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

NCT03190174 COMPLETED

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Sarcoma Oncology Research Center, LLC

NCT00583349 COMPLETED

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

Columbia University

NCT04666688 COMPLETED

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

NCT01489813 COMPLETED

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Emory University

NCT02662062 COMPLETED

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

NCT03240016 COMPLETED

Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

University of Michigan Rogel Cancer Center

NCT03272217 TERMINATED

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Arjun Balar, MD

NCT04228042 TERMINATED

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

M.D. Anderson Cancer Center

NCT03425201 COMPLETED

Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)

Fundacion CRIS de Investigación para Vencer el Cáncer

NCT04871529 TERMINATED

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

SWOG Cancer Research Network

NCT04064190 WITHDRAWN

Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

MedPacto, Inc.

NCT03702179 COMPLETED

Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Spanish Oncology Genito-Urinary Group

NCT02891161 TERMINATED

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Monika Joshi, MD

NCT03534804 COMPLETED

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

University of Utah

NCT03486197 TERMINATED

Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma

University of Washington

NCT03658304 COMPLETED

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

University of Florida

NCT04004221 COMPLETED

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

BeiGene

NCT04690699 TERMINATED

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

Istari Oncology, Inc.

NCT05012397 TERMINATED

Milademetan in Advanced/Metastatic Solid Tumors

Rain Oncology Inc

NCT03207867 TERMINATED

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Novartis Pharmaceuticals

NCT06424717 WITHDRAWN

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

EMD Serono Research & Development Institute, Inc.

NCT05390645 WITHDRAWN

A Study of MFA-370 in Patients with Metastatic Urothelial Cancer

Ectin Research AB

NCT04387461 COMPLETED

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

CG Oncology, Inc.

NCT02177695 COMPLETED

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

SWOG Cancer Research Network

NCT04593862 COMPLETED

Bladder Cancer and ExeRcise Training During IntraVesical ThErapy

University of Alberta

NCT00981656 COMPLETED

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Radiation Therapy Oncology Group

NCT01284348 TERMINATED

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Merck Sharp & Dohme LLC

NCT03219333 COMPLETED

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Astellas Pharma Inc

NCT05574504 WITHDRAWN

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

AdventHealth

NCT03513952 COMPLETED

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

NCT02091141 COMPLETED

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

NCT01625260 TERMINATED

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Altor BioScience

NCT03557918 COMPLETED

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Matthew Galsky

NCT03558087 COMPLETED

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Matthew Galsky

NCT03319745 COMPLETED

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

M.D. Anderson Cancer Center

NCT04525131 COMPLETED

Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors

CicloMed LLC

NCT03451331 COMPLETED

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Matthew Galsky

NCT04742959 COMPLETED

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

TransThera Sciences (Nanjing), Inc.

NCT03311334 TERMINATED

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Sumitomo Pharma America, Inc.

NCT05338580 WITHDRAWN

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

TJ Biopharma Co., Ltd.

NCT03472560 TERMINATED

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Pfizer

NCT02108652 COMPLETED

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)

Hoffmann-La Roche

NCT02951767 COMPLETED

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

Hoffmann-La Roche

NCT03339843 COMPLETED

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

Jules Bordet Institute

NCT03665285 COMPLETED

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NextCure, Inc.

NCT06018116 WITHDRAWN

A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.

CHU de Quebec-Universite Laval

NCT03892642 COMPLETED

Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

University of Oklahoma

NCT03891238 COMPLETED

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study

Consorzio Oncotech

NCT03511391 COMPLETED

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors

University Hospital, Ghent

NCT03992131 TERMINATED

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

pharmaand GmbH

NCT04672330 COMPLETED

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

RenJi Hospital

NCT04496219 COMPLETED

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Fred Hutchinson Cancer Center

NCT04073602 COMPLETED

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

RemeGen Co., Ltd.

NCT02030067 COMPLETED

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

Processa Pharmaceuticals

NCT02795156 COMPLETED

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

SCRI Development Innovations, LLC

NCT02887248 TERMINATED

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

SCRI Development Innovations, LLC

NCT03809013 COMPLETED

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

RemeGen Co., Ltd.

NCT01215136 TERMINATED

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Matthew Galsky

NCT03448718 COMPLETED

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Matthew Galsky

NCT02599324 COMPLETED

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Pharmacyclics LLC.

NCT02527434 COMPLETED

Study of Tremelimumab in Patients With Advanced Solid Tumors

AstraZeneca

NCT02232646 WITHDRAWN

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Sumitomo Pharma America, Inc.

NCT06050954 WITHDRAWN

A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)

Fox Chase Cancer Center

NCT05120622 WITHDRAWN

Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer

University of British Columbia

NCT06090318 WITHDRAWN

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Rain Oncology Inc

NCT03390595 COMPLETED

Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma

Associació per a la Recerca Oncologica, Spain

NCT04045613 COMPLETED

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

Basilea Pharmaceutica

NCT03737123 TERMINATED

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Nabil Adra

NCT03639714 COMPLETED

A Study of a Personalized Neoantigen Cancer Vaccine

Gritstone bio, Inc.

NCT03912818 TERMINATED

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

NCT03317496 TERMINATED

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Pfizer

NCT03606174 TERMINATED

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Mirati Therapeutics Inc.

NCT02033993 COMPLETED

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

Canadian Cancer Trials Group

NCT03636256 COMPLETED

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

NanOlogy, LLC

NCT03421652 COMPLETED

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

Barbara Ann Karmanos Cancer Institute

NCT04639245 TERMINATED

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Fred Hutchinson Cancer Center

NCT03602079 COMPLETED

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

NCT03576131 TERMINATED

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Genmab

NCT04424641 TERMINATED

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Genmab

NCT03679767 COMPLETED

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Incyte Corporation

NCT02412670 COMPLETED

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

ECOG-ACRIN Cancer Research Group

NCT03735680 COMPLETED

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

OncoNano Medicine, Inc.

NCT03397394 TERMINATED

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

pharmaand GmbH

NCT03637803 TERMINATED

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

4D pharma plc

NCT05107427 WITHDRAWN

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

4D pharma plc

NCT05496192 WITHDRAWN

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Bristol-Myers Squibb

NCT03472274 COMPLETED

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

Fundacion CRIS de Investigación para Vencer el Cáncer

NCT02371447 COMPLETED

VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

Swiss Cancer Institute

NCT04209192 COMPLETED

Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

NCT02983045 COMPLETED

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

Nektar Therapeutics

NCT02335424 COMPLETED

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Merck Sharp & Dohme LLC

NCT02281383 COMPLETED

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT03058757 COMPLETED

The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation

National Cancer Center, Korea

NCT03212651 COMPLETED

Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab

Gustave Roussy, Cancer Campus, Grand Paris

NCT03617913 COMPLETED

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Mayo Clinic

NCT02393248 TERMINATED

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

NCT04851834 TERMINATED

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Xennials Therapeutics Australia Pty Ltd

NCT05219578 TERMINATED

RTX-224 Monotherapy in Patients With Solid Tumors

Rubius Therapeutics

NCT02643303 COMPLETED

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

NCT03464734 COMPLETED

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

NCT00805129 COMPLETED

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Memorial Sloan Kettering Cancer Center

NCT03980041 COMPLETED

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Infinity Pharmaceuticals, Inc.

NCT02876861 COMPLETED

Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC

Xiangya Hospital of Central South University

NCT01688999 COMPLETED

Cabozantinib for Advanced Urothelial Cancer

National Cancer Institute (NCI)

NCT02500121 COMPLETED

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Matthew Galsky

NCT03558503 COMPLETED

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

UroGen Pharma Ltd.

NCT02901548 TERMINATED

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

H. Lee Moffitt Cancer Center and Research Institute

NCT01732107 TERMINATED

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Noah Hahn, M.D.

NCT01524991 COMPLETED

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Hoosier Cancer Research Network

NCT01780545 COMPLETED

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Noah Hahn, M.D.

NCT00777491 COMPLETED

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Radiation Therapy Oncology Group

NCT03945084 COMPLETED

Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy

University of Turin, Italy

NCT03628716 COMPLETED

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Bavarian Nordic

NCT03633110 COMPLETED

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Genocea Biosciences, Inc.

NCT05234606 WITHDRAWN

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Silverback Therapeutics

NCT02111850 COMPLETED

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

National Cancer Institute (NCI)

NCT04501094 TERMINATED

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

National Cancer Institute (NCI)

NCT01126749 TERMINATED

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Eisai Inc.

NCT02178722 COMPLETED

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

NCT02318277 COMPLETED

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Incyte Corporation

NCT01093066 TERMINATED

Prospective Multicentric Evaluation of a Bladder Preservation Strategy

Centre Hospitalier Universitaire de Saint Etienne

NCT02001623 COMPLETED

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

NCT03294304 COMPLETED

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Masonic Cancer Center, University of Minnesota

NCT03287050 TERMINATED

Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

University of Michigan Rogel Cancer Center

NCT03430895 COMPLETED

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Memorial Sloan Kettering Cancer Center

NCT03520231 COMPLETED

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

University Health Network, Toronto

NCT04555343 COMPLETED

Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention

Fraser Health

NCT03245736 COMPLETED

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen Inc.

NCT02792192 TERMINATED

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Hoffmann-La Roche

NCT03115801 TERMINATED

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Weill Medical College of Cornell University

NCT04066595 TERMINATED

Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

Johannes Gutenberg University Mainz

NCT00694915 COMPLETED

Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder

Cadila Pharnmaceuticals

NCT04579133 TERMINATED

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Latin American Cooperative Oncology Group

NCT04131634 TERMINATED

Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer

University of Texas Southwestern Medical Center

NCT02009332 COMPLETED

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Aadi Bioscience, Inc.

NCT02693717 TERMINATED

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer

M.D. Anderson Cancer Center

NCT04464967 WITHDRAWN

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

NCT01827943 COMPLETED

Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

Institut Bergonié

NCT02365818 COMPLETED

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

CG Oncology, Inc.

NCT02552121 COMPLETED

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

NCT03832673 WITHDRAWN

Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

NCT04184232 COMPLETED

Treatment of Recurrent Bladder Cancer With Dendritic Cells

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

NCT02197897 COMPLETED

Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors

Baylor College of Medicine

NCT00790426 COMPLETED

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Novartis Pharmaceuticals

NCT02788201 COMPLETED

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

National Cancer Institute (NCI)

NCT00749892 COMPLETED

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

M.D. Anderson Cancer Center

NCT03498196 TERMINATED

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

Baylor College of Medicine

NCT03719300 TERMINATED

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Anchiano Therapeutics Israel Ltd.

NCT04498702 COMPLETED

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

Jiangsu Yahong Meditech Co., Ltd aka Asieris

NCT02459119 COMPLETED

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

University of Alabama at Birmingham

NCT03167151 TERMINATED

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

University of Oxford

NCT03672240 COMPLETED

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

Asieris Pharmaceutical Technologies Co., Ltd.

NCT03234153 TERMINATED

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Insel Gruppe AG, University Hospital Bern

NCT03517995 WITHDRAWN

Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention

H. Lee Moffitt Cancer Center and Research Institute

NCT03534492 COMPLETED

Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)

Spanish Oncology Genito-Urinary Group

NCT02028442 COMPLETED

Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients

Akamis Bio

NCT02010203 TERMINATED

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Heat Biologics

NCT01094496 TERMINATED

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

Celldex Therapeutics

NCT03007719 TERMINATED

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Lawrence Fong

NCT03935347 WITHDRAWN

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Roswell Park Cancer Institute

NCT00722553 COMPLETED

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Acrotech Biopharma Inc.

NCT04040725 WITHDRAWN

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Dana-Farber Cancer Institute

NCT02178241 COMPLETED

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT01520038 COMPLETED

Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer

Abramson Cancer Center at Penn Medicine

NCT02665039 COMPLETED

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function

Dr Anders Ullén

NCT01589094 COMPLETED

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT00794950 COMPLETED

Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma

University of Michigan

NCT01031420 COMPLETED

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Fox Chase Cancer Center

NCT02351739 COMPLETED

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

Acerta Pharma BV

NCT02141490 COMPLETED

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

National Cancer Institute (NCI)

NCT02999672 COMPLETED

A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors

Hoffmann-La Roche

NCT03507166 COMPLETED

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

RemeGen Co., Ltd.

NCT01373294 COMPLETED

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT01611662 TERMINATED

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Fox Chase Cancer Center

NCT02153905 TERMINATED

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Cancer Institute (NCI)

NCT03029832 TERMINATED

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Genentech, Inc.

NCT01191892 COMPLETED

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Cardiff University

NCT01118351 TERMINATED

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Case Comprehensive Cancer Center

NCT00595088 COMPLETED

Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Anchiano Therapeutics Israel Ltd.

NCT02109328 COMPLETED

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

NCT03419130 WITHDRAWN

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

NCT02334527 TERMINATED

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

UNC Lineberger Comprehensive Cancer Center

NCT01089088 COMPLETED

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Cardiff University

NCT02605863 TERMINATED

Enzalutamide for Bladder Cancer Chemoprevention

University of Rochester

NCT00578526 COMPLETED

SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial

AHS Cancer Control Alberta

NCT01331824 TERMINATED

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Matthew Galsky

NCT01234519 TERMINATED

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

AEterna Zentaris

NCT01259063 COMPLETED

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

Memorial Sloan Kettering Cancer Center

NCT02845050 WITHDRAWN

Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)

Ligartis GmbH

NCT01090466 COMPLETED

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Cardiff University

NCT00666562 COMPLETED

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

National Cancer Institute (NCI)

NCT01938573 COMPLETED

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

University of Washington

NCT03150836 WITHDRAWN

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Terence Friedlander, MD

NCT02655081 COMPLETED

Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy

University of Pittsburgh

NCT02236195 COMPLETED

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Mirati Therapeutics Inc.

NCT01622660 TERMINATED

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Memorial Sloan Kettering Cancer Center

NCT01687244 COMPLETED

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

FKD Therapies Oy

NCT01042795 TERMINATED

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

University of Michigan

NCT02307487 COMPLETED

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

NCT01108055 COMPLETED

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Sandy Srinivas

NCT01353222 TERMINATED

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

NCT01328574 COMPLETED

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

NCT02661100 WITHDRAWN

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Case Comprehensive Cancer Center

NCT00821327 COMPLETED

Gemzar, Cisp, Sunitinib Urothelial Ca

US Oncology Research

NCT00808639 COMPLETED

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Dana-Farber Cancer Institute

NCT01454089 COMPLETED

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Achieve Life Sciences

NCT02030574 TERMINATED

Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

Brown University

NCT01339000 TERMINATED

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

National Cancer Institute (NCI)

NCT01801137 COMPLETED

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium

Hopital Foch

NCT00645593 COMPLETED

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

University of Michigan Rogel Cancer Center

NCT02718742 WITHDRAWN

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Mayo Clinic

NCT02479178 TERMINATED

A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

BIND Therapeutics

NCT00847015 COMPLETED

Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT01916109 TERMINATED

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

NCT01663285 TERMINATED

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

University of Michigan Rogel Cancer Center

NCT00714948 TERMINATED

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Memorial Sloan Kettering Cancer Center

NCT00635726 TERMINATED

Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

Hellenic Oncology Research Group

NCT00995488 TERMINATED

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

University of Michigan Rogel Cancer Center

NCT01071928 WITHDRAWN

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Hoosier Cancer Research Network

NCT01374789 TERMINATED

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer

WiSP Wissenschaftlicher Service Pharma GmbH

NCT01600339 COMPLETED

A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)

Rambam Health Care Campus

NCT00933374 TERMINATED

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma

Heinrich-Heine University, Duesseldorf

NCT01731652 COMPLETED

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Telormedix SA

NCT01490437 COMPLETED

Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma

Asan Medical Center

NCT00471536 COMPLETED

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

NCT01711112 COMPLETED

Salvage Docetaxel for Pretreated Urothelial Cancer

Samsung Medical Center

NCT01907308 WITHDRAWN

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

University of Colorado, Denver

NCT01639521 WITHDRAWN

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

University of Southern California

NCT01939756 COMPLETED

Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms

Savino M. Di Stasi

NCT01031875 COMPLETED

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

NCT01700010 WITHDRAWN

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

University of Michigan Rogel Cancer Center

NCT01551407 TERMINATED

Detection of Bladder Tumors After 30 Min Instillation of Hexvix

Photocure

NCT01265940 COMPLETED

Pazopanib and Vinflunine in Urothelial Cancer of the Bladder

Prof. Dr. Thomas Otto

NCT00792025 COMPLETED

Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer

Institut Curie

NCT00661609 COMPLETED

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

AstraZeneca

NCT02496208 ACTIVE NOT RECRUITING

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

NCT06439836 RECRUITING

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

National Cancer Institute (NCI)

NCT04963153 ACTIVE NOT RECRUITING

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

NCT06465069 RECRUITING

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Eli Lilly and Company

NCT05581004 RECRUITING

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

NCT06257264 RECRUITING

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeiGene

NCT05126472 RECRUITING

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Memorial Sloan Kettering Cancer Center

NCT03132922 ACTIVE NOT RECRUITING

MAGE-A4ᶜ¹º³²T for Multi-Tumor

USWM CT, LLC

NCT05154994 ACTIVE NOT RECRUITING

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

University of Utah

NCT05521698 RECRUITING

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

University of Wisconsin, Madison

NCT04620603 ACTIVE NOT RECRUITING

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Case Comprehensive Cancer Center

NCT07416123 RECRUITING

A Study of GEN1106 in Participants With Solid Tumors

Genmab

NCT07218003 ENROLLING BY INVITATION

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Rondo Therapeutics

NCT04878029 RECRUITING

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Emory University

NCT07555769 NOT YET RECRUITING

Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial

Juan Luis Vásquez

NCT04388852 ACTIVE NOT RECRUITING

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

M.D. Anderson Cancer Center

NCT04235777 RECRUITING

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

National Cancer Institute (NCI)

NCT07545122 NOT YET RECRUITING

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

Context Therapeutics Inc.

NCT05562791 RECRUITING

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Memorial Sloan Kettering Cancer Center

NCT07353294 ENROLLING BY INVITATION

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT07020117 RECRUITING

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Aktis Oncology, Inc.

NCT06966024 RECRUITING

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Deciphera Pharmaceuticals, LLC

NCT07206225 RECRUITING

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Pfizer

NCT05929235 RECRUITING

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Flare Therapeutics Inc.

NCT07532902 RECRUITING

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

NCT05483868 RECRUITING

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Aura Biosciences

NCT07518043 NOT YET RECRUITING

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Shanghai Henlius Biotech

NCT01366144 ACTIVE NOT RECRUITING

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

NCT07217171 RECRUITING

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

EvolveImmune United, Inc

NCT04491942 ACTIVE NOT RECRUITING

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

NCT06582017 RECRUITING

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Nammi Therapeutics Inc

NCT06238479 ACTIVE NOT RECRUITING

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Eli Lilly and Company

NCT06253871 RECRUITING

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Iambic Therapeutics, Inc

NCT05858736 ACTIVE NOT RECRUITING

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

OncoC4, Inc.

NCT06444815 RECRUITING

A Study of VET3-TGI in Patients With Solid Tumors

KaliVir Immunotherapeutics

NCT07484022 RECRUITING

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

NCT07090499 RECRUITING

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Pfizer

NCT04044859 ACTIVE NOT RECRUITING

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

USWM CT, LLC

NCT07277413 RECRUITING

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

IDEAYA Biosciences

NCT06451497 RECRUITING

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

NCT07140315 RECRUITING

DK222 Study at Hopkins

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06253845 ACTIVE NOT RECRUITING

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

H. Lee Moffitt Cancer Center and Research Institute

NCT05891171 ACTIVE NOT RECRUITING

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Arcus Biosciences, Inc.

NCT07492628 RECRUITING

Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

Beijing Biotech

NCT04514484 ACTIVE NOT RECRUITING

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

NCT06293898 RECRUITING

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

SystImmune Inc.

NCT07483970 NOT YET RECRUITING

A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.

Jecho Biopharmaceuticals Co., Ltd.

NCT05055050 ACTIVE NOT RECRUITING

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

M.D. Anderson Cancer Center

NCT04007744 ACTIVE NOT RECRUITING

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Mayo Clinic

NCT04004442 ACTIVE NOT RECRUITING

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

University of Oklahoma

NCT05833867 RECRUITING

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Shilpa Gupta, MD

NCT05843448 RECRUITING

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

University of California, Davis

NCT06173349 RECRUITING

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

University of California, Davis

NCT05176483 RECRUITING

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis

NCT07227168 RECRUITING

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Sutro Biopharma, Inc.

NCT06910657 RECRUITING

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

NCT03252938 ACTIVE NOT RECRUITING

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

NCT06778863 RECRUITING

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Clasp Therapeutics, Inc.

NCT03740256 RECRUITING

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Baylor College of Medicine

NCT06242470 RECRUITING

A Study of MGC026 in Participants With Advanced Solid Tumors

MacroGenics

NCT04459273 ACTIVE NOT RECRUITING

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Jonsson Comprehensive Cancer Center

NCT04969835 RECRUITING

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Avacta Life Sciences Ltd

NCT06771219 RECRUITING

SLV-154 Treatment of Metastatic Solid Tumors

Solve Therapeutics

NCT07359235 RECRUITING

Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)

Tongji Hospital

NCT06999187 RECRUITING

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Bio

NCT02560636 ACTIVE NOT RECRUITING

Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer

Royal Marsden NHS Foundation Trust

NCT02546661 ACTIVE NOT RECRUITING

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

AstraZeneca

NCT06022029 RECRUITING

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

OncoNano Medicine, Inc.

NCT05768347 ACTIVE NOT RECRUITING

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

H. Lee Moffitt Cancer Center and Research Institute

NCT07260162 NOT YET RECRUITING

Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)

Institut Cancerologie de l'Ouest

NCT02869217 ACTIVE NOT RECRUITING

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

University Health Network, Toronto

NCT03983954 ACTIVE NOT RECRUITING

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

NCT07252661 NOT YET RECRUITING

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

AccSalus Biosciences, Inc.

NCT06332755 RECRUITING

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

LG Chem

NCT03582475 ACTIVE NOT RECRUITING

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Jonsson Comprehensive Cancer Center

NCT06714617 ACTIVE NOT RECRUITING

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

SystImmune Inc.

NCT06848868 RECRUITING

Ambulatory Flexible URS for UTUC Surveillance

Chinese University of Hong Kong

NCT06351904 RECRUITING

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Ractigen Therapeutics.

NCT05107674 RECRUITING

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

NCT05519241 RECRUITING

A Phase I Intravesical PPM Therapy for NMIBC

VA Office of Research and Development

NCT06181266 ACTIVE NOT RECRUITING

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Prokarium Ltd

NCT06036121 ACTIVE NOT RECRUITING

A Study of ADRX-0706 in Select Advanced Solid Tumors

Adcentrx Therapeutics

NCT03170960 ACTIVE NOT RECRUITING

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

NCT07118176 RECRUITING

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

NCT03872947 ACTIVE NOT RECRUITING

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

NCT06337084 RECRUITING

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Monopar Therapeutics

NCT06617169 RECRUITING

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Monopar Therapeutics

NCT06586255 RECRUITING

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

Abramson Cancer Center at Penn Medicine

NCT06916494 RECRUITING

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

First Affiliated Hospital of Chongqing Medical University

NCT06766266 RECRUITING

Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

First Affiliated Hospital of Chongqing Medical University

NCT03212404 ACTIVE NOT RECRUITING

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

NCT06186414 RECRUITING

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Jiangsu Simcere Pharmaceutical Co., Ltd.

NCT03096054 ACTIVE NOT RECRUITING

A CR-UK Phase I Trial of LY3143921

Cancer Research UK

NCT06108492 RECRUITING

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Shanghai Hengrui Pharmaceutical Co., Ltd.

NCT05215574 ACTIVE NOT RECRUITING

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

NCT06632964 RECRUITING

A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer

The Affiliated Hospital of Xuzhou Medical University

NCT05867303 ACTIVE NOT RECRUITING

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

RemeGen Co., Ltd.

NCT06551233 RECRUITING

Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT04432857 ACTIVE NOT RECRUITING

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

NCT06427291 RECRUITING

Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients

Fudan University

NCT04134000 ACTIVE NOT RECRUITING

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Fundacion Oncosur

NCT05979909 NOT YET RECRUITING

Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma

McMaster University

NCT01552434 TERMINATED

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

NCT02298153 TERMINATED

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

Incyte Corporation

NCT05861947 TERMINATED

A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

Aurigene Discovery Technologies Limited

NCT03236935 COMPLETED

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

NCT05839119 TERMINATED

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

Brown University

NCT04234113 TERMINATED

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

SOTIO Biotech AG

NCT06580938 TERMINATED

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Pfizer

NCT07217496 WITHDRAWN

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Vadim S Koshkin

NCT06963346 SUSPENDED

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

H. Lee Moffitt Cancer Center and Research Institute

NCT01104350 COMPLETED

Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Memorial Sloan Kettering Cancer Center

NCT04610671 COMPLETED

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

H. Lee Moffitt Cancer Center and Research Institute

NCT05233436 TERMINATED

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Pfizer

NCT02989064 COMPLETED

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Adaptimmune

NCT05375903 COMPLETED

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

UroGen Pharma Ltd.

NCT03575013 COMPLETED

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

Yousef Zakharia

NCT05014139 TERMINATED

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Astellas Pharma Global Development, Inc.

NCT04272034 TERMINATED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Incyte Corporation

NCT06285097 TERMINATED

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Pfizer

NCT04344795 COMPLETED

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Tempest Therapeutics

NCT02475213 COMPLETED

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

MacroGenics

NCT05585034 COMPLETED

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Xencor, Inc.

NCT02903914 COMPLETED

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Incyte Corporation

NCT02885974 COMPLETED

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer

Baylor College of Medicine

NCT05524545 COMPLETED

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

ALX Oncology Inc.

NCT03617003 COMPLETED

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

Memorial Sloan Kettering Cancer Center

NCT04242199 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Incyte Corporation

NCT04116320 TERMINATED

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Craig L Slingluff, Jr

NCT04580485 COMPLETED

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Incyte Corporation

NCT03289962 COMPLETED

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Genentech, Inc.

NCT06630247 TERMINATED

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Exelixis

NCT06816017 WITHDRAWN

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Hoffmann-La Roche

NCT05788484 COMPLETED

A Study of CDX-585 in Patients With Advanced Malignancies

Celldex Therapeutics

NCT06100653 COMPLETED

BCG for Therapeutic Use Phase I Clinical Trial

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

NCT04152018 TERMINATED

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Pfizer

NCT05242822 TERMINATED

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Kinnate Biopharma

NCT03473756 COMPLETED

Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma

Bayer

NCT05940844 WITHDRAWN

Study of OB-002 in Patients With Refractory Metastatic Cancer

Orion Biotechnology Polska Sp. z o.o.

NCT03894618 COMPLETED

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Shattuck Labs, Inc.

NCT03387761 COMPLETED

Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy

The Netherlands Cancer Institute

NCT04871594 COMPLETED

Pre-operative Immunotherapy in Stage II-III Urothelial Cancer

The Netherlands Cancer Institute

NCT04254107 TERMINATED

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Seagen Inc.

NCT03523572 COMPLETED

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Daiichi Sankyo

NCT05085977 COMPLETED

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Protara Therapeutics

NCT05085990 COMPLETED

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Protara Therapeutics

NCT05279690 COMPLETED

Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors

Icahn School of Medicine at Mount Sinai

NCT04164069 COMPLETED

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Anne Noonan

NCT06448364 TERMINATED

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

Pfizer

NCT01963052 COMPLETED

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Astellas Pharma Global Development, Inc.

NCT02091999 COMPLETED

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Astellas Pharma Global Development, Inc.

NCT06034860 TERMINATED

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Molecular Templates, Inc.

NCT03960060 TERMINATED

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

Shanghai PerHum Therapeutics Co., Ltd.

NCT03070990 COMPLETED

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Astellas Pharma Inc

NCT04713891 COMPLETED

A Study of KF-0210 in Advanced Solid Tumors Patients

Keythera Pharmaceuticals (Australia) Pty Ltd

NCT05655598 WITHDRAWN

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Brown University

NCT03532451 COMPLETED

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

PrECOG, LLC.

NCT02324582 COMPLETED

MK-3475/BCG in High Risk Superficial Bladder Cancer

Southern Illinois University

NCT04548193 COMPLETED

Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship

Roswell Park Cancer Institute

NCT03518320 TERMINATED

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

Taris Biomedical LLC

NCT04628780 TERMINATED

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Pfizer

NCT02826564 COMPLETED

Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer

University Hospital, Ghent

NCT05738161 WITHDRAWN

Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma

Insel Gruppe AG, University Hospital Bern

NCT03752398 COMPLETED

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Xencor, Inc.

NCT02808143 COMPLETED

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Northwestern University

NCT03621982 TERMINATED

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

ADC Therapeutics S.A.

NCT03629756 COMPLETED

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

NCT03915405 TERMINATED

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Kyowa Kirin, Inc.

NCT05046665 COMPLETED

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

South Metropolitan Health Service

NCT03650348 COMPLETED

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Pieris Pharmaceuticals, Inc.

NCT03330561 COMPLETED

PRS-343 in HER2-Positive Solid Tumors

Pieris Pharmaceuticals, Inc.

NCT05894447 WITHDRAWN

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Weill Medical College of Cornell University

NCT05061537 TERMINATED

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Pfizer

NCT06350838 COMPLETED

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

Chengdu CoenBiotech Co., Ltd

NCT03329950 COMPLETED

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

NCT03590054 COMPLETED

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Rahul Aggarwal

NCT04200963 COMPLETED

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Ikena Oncology

NCT04244552 TERMINATED

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Atreca, Inc.

NCT04187872 TERMINATED

LITT and Pembrolizumab in Recurrent Brain Metastasis

University of Florida

NCT03454451 COMPLETED

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

NCT02482168 COMPLETED

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

NCT03229278 COMPLETED

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Rutgers, The State University of New Jersey

NCT04602117 WITHDRAWN

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

QuantumLeap Healthcare Collaborative

NCT02897375 COMPLETED

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Emory University

NCT02722538 COMPLETED

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

Taris Biomedical LLC

NCT04601402 COMPLETED

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Genome & Company

NCT04452214 COMPLETED

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

Cantargia AB

NCT03191578 COMPLETED

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®

Archivel Farma S.L.

NCT03829436 COMPLETED

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Tempest Therapeutics

NCT03171493 COMPLETED

Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

Vyriad, Inc.

NCT03552796 WITHDRAWN

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

University of Southern California

NCT04440943 COMPLETED

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Celldex Therapeutics

NCT03359239 COMPLETED

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Matthew Galsky

NCT02043665 COMPLETED

CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)

Viralytics

NCT03841110 COMPLETED

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

NCT03758781 COMPLETED

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

H. Lee Moffitt Cancer Center and Research Institute

NCT03849469 COMPLETED

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Xencor, Inc.

NCT03775850 COMPLETED

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Evelo Biosciences, Inc.

NCT05259397 WITHDRAWN

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Pfizer

NCT03854721 COMPLETED

A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer

Vaxiion Therapeutics

NCT03689192 COMPLETED

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

Herlev Hospital

NCT03265080 TERMINATED

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Advaxis, Inc.

NCT04430842 COMPLETED

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

NCT03517488 COMPLETED

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Xencor, Inc.

NCT02437370 COMPLETED

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

University of California, Davis

NCT03773666 COMPLETED

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Dana-Farber Cancer Institute

NCT04060342 TERMINATED

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

NCT04972253 WITHDRAWN

Phase I BLASST-3 Trial

Guru P. Sonpavde

NCT02316171 COMPLETED

CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

Viralytics

NCT04596033 TERMINATED

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Genocea Biosciences, Inc.

NCT04173338 TERMINATED

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Augusta University

NCT03023319 COMPLETED

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Nagla Abdel Karim

NCT02646748 COMPLETED

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

NCT03985072 COMPLETED

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

Andes Biotechnologies

NCT01391143 COMPLETED

Safety Study of MGA271 in Refractory Cancer

MacroGenics

NCT02628535 TERMINATED

Safety Study of MGD009 in B7-H3-expressing Tumors

MacroGenics

NCT04316689 COMPLETED

First-in-human Study of S-588210 (S-488210+S-488211)

Shionogi

NCT02573259 COMPLETED

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Pfizer

NCT02767921 TERMINATED

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

University of Southern California

NCT03652077 COMPLETED

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Incyte Corporation

NCT04601766 COMPLETED

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Asieris Pharmaceuticals (AUS) Pty Ltd.

NCT02897765 COMPLETED

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

BioNTech US Inc.

NCT03125200 TERMINATED

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

ADC Therapeutics S.A.

NCT02608125 TERMINATED

A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

Principia Biopharma, a Sanofi Company

NCT03538028 COMPLETED

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Incyte Biosciences International Sàrl

NCT02346955 TERMINATED

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Famewave Ltd.

NCT03430687 WITHDRAWN

Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

University of California, San Francisco

NCT02092948 COMPLETED

Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

Jonsson Comprehensive Cancer Center

NCT03407976 TERMINATED

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

University of Utah

NCT04073160 WITHDRAWN

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer

Daniel George, MD

NCT04089163 WITHDRAWN

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Tocagen Inc.

NCT02053220 COMPLETED

Mechanism of Action Trial of ColoAd1

Akamis Bio

NCT02720367 COMPLETED

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

Taris Biomedical LLC

NCT02576665 TERMINATED

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Tocagen Inc.

NCT00880854 WITHDRAWN

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

University of Wisconsin, Madison

NCT01004224 COMPLETED

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Novartis Pharmaceuticals

NCT02300610 COMPLETED

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT01844947 COMPLETED

Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Dr Anders Ullén

NCT02880345 WITHDRAWN

RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Abramson Cancer Center at Penn Medicine

NCT02863913 WITHDRAWN

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Peking University

NCT03053635 COMPLETED

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Theralase® Technologies Inc.

NCT03106610 TERMINATED

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

M.D. Anderson Cancer Center

NCT02543645 TERMINATED

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Celldex Therapeutics

NCT03007771 WITHDRAWN

Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia

Washington University School of Medicine

NCT02852564 COMPLETED

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

Eugene Lee, MD

NCT02925533 TERMINATED

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Mark Pomerantz, MD

NCT01162785 COMPLETED

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

M.D. Anderson Cancer Center

NCT01522820 COMPLETED

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Roswell Park Cancer Institute

NCT01606345 COMPLETED

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT01182168 COMPLETED

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

Memorial Sloan Kettering Cancer Center

NCT02437539 COMPLETED

Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography

Rigshospitalet, Denmark

NCT01498172 COMPLETED

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

Patrice Jichlinski

NCT01087697 COMPLETED

Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit

Tengion

NCT01496534 TERMINATED

Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

Matthew Galsky

NCT01282333 TERMINATED

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

NCT01458847 COMPLETED

Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer

BioCis Pharma Ltd

NCT00694798 COMPLETED

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder

Cadila Pharnmaceuticals

NCT01373398 COMPLETED

Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)

Handok Inc.

NCT00782587 COMPLETED

Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer

Halozyme Therapeutics

NCT06862219 RECRUITING

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Astellas Pharma Global Development, Inc.

NCT06764095 RECRUITING

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

NCT05962541 RECRUITING

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

University of Roma La Sapienza

NCT06781879 RECRUITING

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer

Jakob Kristian Jakobsen

NCT04532606 RECRUITING

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Peking University First Hospital

NCT06820255 RECRUITING

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

NCT06709196 RECRUITING

Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

Rigshospitalet, Denmark

NCT06548438 NOT YET RECRUITING

The Impact of PDD During TURB for NMIBC

A.O.U. Città della Salute e della Scienza

NCT03348969 COMPLETED

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

Jørgen Bjerggaard Jensen

NCT06767982 COMPLETED

Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)

Ankara University

NCT06390111 WITHDRAWN

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Ferring Pharmaceuticals

NCT04197089 COMPLETED

Biological Effect of Vitamin D in Patients With Urothelial Carcinoma

Germans Trias i Pujol Hospital

NCT03138967 COMPLETED

Investigation of Sugammadex in Outpatient Urological Procedures

M.D. Anderson Cancer Center

NCT03147599 COMPLETED

Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders

Mansoura University

NCT02001857 COMPLETED

Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.

University Hospital, Ghent

NCT00785694 WITHDRAWN

Recurrence of Bladder Cancer After Transurethral Resection With Hexvix

GE Healthcare

Full Bladder Cancer Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only